bacterial infections

Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.

The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.

The Nasdaq has told the firm that it is in compliance with all applicable listing standards and that its meeting with a hearings panel has been cancelled.

The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.

The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.

The firm hopes its newly launched DxWound will improve pathogen detection in skin and soft tissue infections by including anaerobic and fungal microbes in its reports.

T2 Biosystems' device will potentially enable 95 percent of patients with bloodstream infections to receive targeted therapy within eight hours of a blood draw.

The Gaithersburg, Maryland-based firm intends to use the proceeds for general corporate purposes, including working capital and product development.

T2 said that the panel will be commercially available in Europe in Q3, and added that it is in the midst of completing a pivotal trial in preparation of a submission to the FDA.

An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.

Pages